CFO SpotlightsCareers of chief financial officers, from the filings. Records as of October 28, 2026

  1. CFO Spotlights
  2. Profiles
  3. Vishwas Setia

Profile

Vishwas Setia

Chief Financial Officer (Principal Financial Officer), MapLight Therapeutics, Inc.

Former. First published here October 28, 2026; built from records as of October 28, 2026.

MapLight Therapeutics, Inc. named Jonathan Gillis to succeed Vishwas Setia on an interim basis, effective June 18, 2026.2

Seats

The seat in the record

CompanyTitle as filedStandingFilings
MapLight Therapeutics, Inc. (MPLT)
Pharmaceutical Preparations
Chief Financial Officer (Principal Financial Officer)Former2

Company names link to the company's page in the record at CFO Tribune, which holds the seat history.

The record

Filing by filing, latest first

  1. June 18, 2026effective

    MapLight Therapeutics, Inc. named Jonathan Gillis to succeed Vishwas Setia on an interim basis, effective June 18, 2026. Profile of Jonathan Gillis.

    Setia, the board of directors of the Company appointed Jonathan Gillis, the Company’s Chief Administrative and Accounting Officer, as the Company’s interim Chief Financial Officer and interim principal financial officer, effective June 18, 2026.

    [2] Filing by MapLight Therapeutics, Inc., filed with the SEC on June 18, 2026. Read the filing. The record at CFO Tribune.

  2. March 26, 202610-K filed

    Vishwas Setia signed the annual report of MapLight Therapeutics, Inc. on Form 10-K as Chief Financial Officer (Principal Financial Officer), filed March 26, 2026.

    /s/ Vishwas Setia Chief Financial Officer March 26, 2026 Vishwas Setia (Principal Financial Officer)

    [1] Annual report on Form 10-K by MapLight Therapeutics, Inc., filed with the SEC on March 26, 2026. Read the filing. The record at CFO Tribune.

Sources

Sources

  1. Annual report on Form 10-K, MapLight Therapeutics, Inc.. U.S. Securities and Exchange Commission, EDGAR, filed March 26, 2026. sec.gov; record.
  2. Current report filed with the SEC, MapLight Therapeutics, Inc.. U.S. Securities and Exchange Commission, EDGAR, filed June 18, 2026. sec.gov; record.

Corrections and removal

If a line here is wrong, or Vishwas Setia wants this profile taken down, write to corrections@cfospotlights.com. Corrections are made on the page with a dated note; removal requests are answered within 72 hours. The underlying filings stay public at the SEC.